[{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Esteve Huayi Pharmaceutical \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Esteve Huayi Pharmaceutical \/ Esteve Pharmaceuticals"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Esteve Huayi Pharmaceutical \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Esteve Huayi Pharmaceutical \/ Esteve Pharmaceuticals"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"Decarboxylase","graph1":"Neurology","graph2":"Approved","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Esteve Huayi Pharmaceutical \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Esteve Huayi Pharmaceutical \/ Esteve Pharmaceuticals"},{"orgOrder":0,"company":"Esteve Quimica","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Esteve Quimica","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Esteve Quimica \/ Acorda Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Esteve Quimica \/ Acorda Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Esteve Quimica

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Inbrija (levodopa) is levodopa/dopa-decarboxylase inhibitor, it is converted to dopamine replacement agent for the intermittent treatment of episodic motor fluctuations of Parkinson disease.

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 07, 2023

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Acorda Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) is indicated in the EU for the intermittent treatment of episodic motor uctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibito...

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 16, 2022

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Acorda Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement, ESTEVE will have the exclusive distribution rights to INBRIJA in Germany and ACORDA will supply the product to ESTEVE. ESTEVE expects to launch INBRIJA in Germany by mid-2022.

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : $5.6 million

                          November 09, 2021

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Acorda Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of the supply agreement, ACORDA will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product.

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 22, 2021

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Acorda Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.

                          Brand Name : E-58425

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 03, 2021

                          Lead Product(s) : Celecoxib,Tramadol Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Kowa Pharmaceuticals America

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank